Balance Sheet
Cash Flow Statement
Gains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Asset Writedowns and Impairment: 2021-2022

Historic Asset Writedowns and Impairment for Mesoblast (MESO) over the last 1 years, with Dec 2022 value amounting to -$100.0 billion.

  • Mesoblast's Asset Writedowns and Impairment rose 50.00% to -$100.0 billion in Q4 2022 from the same period last year, while for Dec 2022 it was $400.0 billion, marking a year-over-year change of. This contributed to the annual value of $500.0 billion for FY2022, which is negligibly% changed negligibly from last year.
  • Mesoblast's Asset Writedowns and Impairment amounted to -$100.0 billion in Q4 2022, which was down 133.33% from $300.0 billion recorded in Q3 2022.
  • Mesoblast's 5-year Asset Writedowns and Impairment high stood at $500.0 billion for Q3 2021, and its period low was -$200.0 billion during Q4 2021.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $100.0 billion (2022), whereas its average is $116.7 billion.
  • The largest annual percentage gain for Mesoblast's Asset Writedowns and Impairment in the last 5 years was 50.00% (2022), contrasted with its biggest fall of 40.00% (2022).
  • Quarterly analysis of 2 years shows Mesoblast's Asset Writedowns and Impairment stood at -$200.0 billion in 2021, then skyrocketed by 50.00% to -$100.0 billion in 2022.
  • Its Asset Writedowns and Impairment was -$100.0 billion in Q4 2022, compared to $300.0 billion in Q3 2022 and $100.0 billion in Q2 2022.